ACELYRIN, INC. Common Stock Net Assets
ACELYRIN, INC. Common Stock net assets. Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has net assets worth $407.23 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($436.50 Million) and total liabilities ($29.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ACELYRIN, INC. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $407.23 Million |
| % of Total Assets | 93.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of ACELYRIN, INC. Common Stock (2021–2024)
Net assets of ACELYRIN, INC. Common Stock from 2021 to 2024. This chart illustrates how ACELYRIN, INC. Common Stock's net assets have evolved over time, based on quarterly financial data. See SLRN net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual net assets of ACELYRIN, INC. Common Stock from 2021 to 2024. For live market cap and overall valuation, see market cap of ACELYRIN, INC. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $458.29 Million | -30.17% |
| 2023-12-31 | $656.34 Million | +689.22% |
| 2022-12-31 | $-111.39 Million | -164.86% |
| 2021-12-31 | $-42.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ACELYRIN, INC. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69463900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ACELYRIN, INC. Common Stock Net Assets Breakdown (December 2024)
ACELYRIN, INC. Common Stock net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-6.00K | 0.00% |
| Other Components | $1.20 Billion | 260.80% |
| Total Equity | $458.29 Million | 100.00% |
ACELYRIN, INC. Common Stock Competitors by Market Cap
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genesis Technology
TWO:6221
|
$229.19 Million |
|
Bioteque
TWO:4107
|
$229.24 Million |
|
Viking Supply Ships AB (publ)
ST:VSSAB-B
|
$229.30 Million |
|
Sarana Meditama Metropolitan
JK:SAME
|
$229.32 Million |
|
BCEG Environmental Remediation Co. Ltd.
SHE:300958
|
$229.13 Million |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
$229.07 Million |
|
Hanoi Beer Alcohol and Beverage JSC
VN:BHN
|
$228.98 Million |
|
Cint Group AB
ST:CINT
|
$228.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACELYRIN, INC. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 656,337,000 to 458,293,000, a change of -198,044,000 (-30.2%).
- Net loss of 248,226,000 reduced equity.
- Other comprehensive income decreased equity by 168,000.
- Other factors increased equity by 50,350,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-248.23 Million | -54.16% |
| Other Comprehensive Income | $-168.00K | -0.04% |
| Other Changes | $50.35 Million | +10.99% |
| Total Change | $- | -30.17% |
Book Value vs Market Value Analysis
This analysis compares ACELYRIN, INC. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.49x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-2.06 | $2.27 | x |
| 2022-12-31 | $-5.45 | $2.27 | x |
| 2023-12-31 | $9.34 | $2.27 | x |
| 2024-12-31 | $4.62 | $2.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACELYRIN, INC. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-54.16%) is below the historical average (-28.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.63 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-239.32 Million |
| 2023 | -58.15% | 0.00% | 0.00x | 1.13x | $-447.27 Million |
| 2024 | -54.16% | 0.00% | 0.00x | 1.07x | $-294.06 Million |
Industry Comparison
This section compares ACELYRIN, INC. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACELYRIN, INC. Common Stock (SLRN) | $407.23 Million | 0.00% | 0.07x | $229.17 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more